Evolus
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 months.
- Recent price momentum is -11.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 9.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2849 U.S. stocks StockVane covers.
Last computed: 2026-11-21 14:27 UTC
Data coverage: 4 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability D+
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 66.3% | Better than 80% |
| Operating margin | -12.7% | Better than 14% |
| Net margin | -17.4% | Better than 13% |
| Return on equity | -148.3% | Better than 4% |
| Return on invested capital | -54.3% | Better than 5% |
Momentum C+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -22.3% | Better than 28% |
| 6-month return | 7.1% | Better than 68% |
| 12-month return (ex latest month) | 8.2% | Better than 43% |
| Distance below 52-week high | 30.0% | Better than 43% |
Financial Health D
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 1.9x | Better than 53% |
| Debt to assets | 68.6% | Better than 6% |
| Interest coverage | -1.6x | Better than 21% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 149.2% | Better than 90% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 7.00
- Open
- 6.85
- Day range
- 6.50 - 7.19
- Avg price
- 6.78
- Volume
- 813.65K
- Turnover
- 5.51M
- Turnover ratei
- 1.71%
- Volume ratioi
- 1.18
- Amplitudei
- 9.86%
- 52-week rangei
- 3.86 - 9.31
Valuation
- P/Ei
- -8.15
- P/E (TTM)i
- -13.58
- P/Bi
- -11.42
- EPSi
- -0.80
- Book value / shi
- -0.57
- Net profit
- -52.95M
- Net assets
- -37.79M
Share structure
- Market cap
- 431.55M
- Float capi
- 310.74M
- Shares out
- 66.19M
- Float sharesi
- 47.66M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2018-02-08
30.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-1.58M net over the window
Short interest
- Shares short
- 6.02M
- % of floati
- 9.12%
- Days to coveri
- 9.38
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Evolus (EOLS)?
Evolus last traded at 6.52. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Evolus's market cap?
About 431.55M.
What is the P/E ratio of Evolus?
The trailing twelve-month P/E is -13.58. The Valuation tab shows it against the stock's own five-year range.
Does Evolus pay a dividend?
Evolus does not currently pay a regular dividend.
Is Evolus a buy according to analysts?
The consensus of 4 analysts is a Buy rating, with an average 12-month price target of 16.25, which implies 149.2% upside from the current price. This is not investment advice.
What is Evolus's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Evolus a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Evolus discussion 0 comments